The Menarini Group a privatelyheld Italian pharmaceutical and diagnostic company announced that it has been granted marketing authorization by the European Commission for ELZONRIS tagraxofusp as a monotherapy for the firstline treatment of adult patients with plasmacytoid blast dendritic cell neopla...
Servier a global and independent pharmaceutical Group and MiNA Therapeutics the pioneer in RNA activation therapeutics announced today a research partnership to identify and develop small activating RNA saRNA therapies for the treatment of neurological disorders
Mitsubishi Tanabe Pharma America Inc MTPA and Aquestive Therapeutics Inc announced a licensing and supply deal for the US rights to commercialize EXSERVAN riluzole an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis ALS
Nexelis a portfolio company of Ampersand Capital Partners and a leading provider of advanced assay development and laboratory testing services in the infectious oncologic and metabolic diseases fields
Junshi Biosciences an innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that US Food and Drug Administration FDA has granted toripalimab Fast Track designation for the firstline treatment of mucosal melanoma
EMD Serono the Healthcare business sector of Merck KGaA Darmstadt Germany in the US and Canada and Pfizer Inc today announced that the European Commission EC has approved BAVENCIO avelumab
Roche today announced that on December it signed a Global Business Partnership Agreement GBP with Sysmex Under this new framework the parties renewed their commitment to the long standing Distribution
Quercis Pharma AG a private clinical stage biopharmaceutical company leveraging its novel antithrombotic platform announced that it has entered into an exclusive worldwide license agreement for two patents with Beth Israel Deaconess Medical Center BIDMC
Analystinclude the changing patent laws as countries aim to become more TRIPS compliant with India updating its law recently and China in the process of doing so through the WTO Increasing globalization of the generics market with Indian companies becoming involved in Europe and the US and vice versa will also provide an opportunity for generics companies
Abstract Background Clinical trials are critical to scientifically evaluate promising new therapies in oncology but patient accrual to these studies is persistently low Patient preference plays an important role in enrollment in these trials We performed this survey to evaluate the perceptions of newly di
This study shows how to obtain elegant uniform coatings with zero visible defects and a practical coating solution for heat sensitive products For More Infromation Click Here
Axsome Therapeutics Inc discovered AXS novel therapy for the treatment of cataplexy in patients with narcolepsy AXS is an oral highly selective and potent norepinephrine reuptake inhibitor AXS developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment
Currently when coating tablets with moisture sensitive actives aqueous film coatings based on PEG PVA and HPMC are recommended to be applied at high product temperatures to overcome the APIs sensitivity Unfortunately this approach can lead to heat degradation of the API and other potential physical tablet coating defects
Modelling and simulation has been growing rapidly in impact and is now actively used by biopharmaceutical companies worldwide for drug development and...